Indigenous Tetanus-Diphtheria Vaccine Launched to Boost National Immunization
India unveils domestically produced tetanus and diphtheria vaccine.
Top Summary
- What happened: Union Health Minister JP Nadda launched an indigenously manufactured tetanus and adult diphtheria (Td) vaccine at the Central Research Institute in Kasauli.
- Why it matters: This launch strengthens India's public health infrastructure and marks a significant step towards self-reliance in the health and pharmaceutical sectors.
- What changes for people: The Td vaccine is now introduced for supply under the Universal Immunisation Programme (UIP), expanding vaccine access.
- Who is affected: Expectant mothers, children, and the Indian healthcare system will benefit, furthering India's position as a global vaccine manufacturer.
Nadda Unveils Made-in-India Td Vaccine
Union Health Minister JP Nadda launched the indigenously manufactured tetanus and adult diphtheria (Td) vaccine on Saturday at the Central Research Institute (CRI) in Kasauli, Himachal Pradesh.
The Td vaccine will be supplied under the Universal Immunisation Programme (UIP).
The CRI will supply 55 lakh doses to the UIP by April. Production is expected to increase in the coming years.
A Boost for Atmanirbhar Bharat
Nadda emphasized that the launch demonstrates progress towards Atmanirbhar Bharat (self-reliant India) in health and medicine.
"The launch marks a significant step towards safeguarding national health security and strengthening India’s public health infrastructure," Nadda stated.
He highlighted that the government, under Prime Minister Narendra Modi, is aiming for self-reliance in the health and pharmaceutical sectors.
India: Pharmacy of the World
Nadda emphasized that India is widely recognized as the "pharmacy of the world".
The country is among the leading vaccine manufacturers globally.
India has achieved Maturity Level 3 in the World Health Organisation’s (WHO) global benchmarking of regulatory systems.
Lessons from COVID-19
Nadda recalled that vaccine development typically takes decades.
During the COVID-19 pandemic, India developed two indigenous vaccines within nine months and administered over 220 crore doses.
India also supplied vaccines to nearly 100 countries under the Vaccine Maitri initiative, with 48 countries receiving them free of cost.
Revitalizing Public Sector Units
CRI is the first Government institute to manufacture vaccines under Good Manufacturing Practices (GMP) standards.
Nadda described the Universal Immunisation Programme (UIP) as the world’s largest immunisation programme.
The UIP currently provides 11 vaccines protecting against 12 vaccine-preventable diseases.
Tracking and Coverage
Each year, approximately 2-2.5 crore children are born and a similar number of women become pregnant.
Beneficiaries are tracked through digital platforms such as U-WIN.
The government ensures that expectant mothers receive five antenatal check-ups.
Vaccine coverage in the country has reached nearly 99 per cent due to systematic tracking and sustained immunisation efforts.
What to Watch Next
The scaling up of Td vaccine production at CRI and its distribution under the UIP will be closely monitored. Further developments in India's vaccine manufacturing capabilities and its impact on global health security are also key areas to watch.